{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:47:10Z","timestamp":1789948030585,"version":"4.0.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (CN)","doi-asserted-by":"publisher","award":["31171211"],"award-info":[{"award-number":["31171211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (CN)","doi-asserted-by":"publisher","award":["81471305"],"award-info":[{"award-number":["81471305"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (CN)","doi-asserted-by":"publisher","award":["81200983"],"award-info":[{"award-number":["81200983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (CN)","doi-asserted-by":"publisher","award":["81301082"],"award-info":[{"award-number":["81301082"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China Medical Foundation","doi-asserted-by":"crossref","award":["2012B09"],"award-info":[{"award-number":["2012B09"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hubei Molecular Imaging Key Laboratory","award":["0203201343"],"award-info":[{"award-number":["0203201343"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12035-015-9601-8","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T13:06:46Z","timestamp":1449839206000},"page":"6698-6708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Induced Pluripotent Stem Cells in Huntington\u2019s Disease: Disease Modeling and the Potential for Cell-Based Therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Ling","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sha","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Cheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"issue":"9557","key":"9601_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/s0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington's disease. Lancet 369(9557):218\u2013228. doi: 10.1016\/s0140-6736(07)60111-1","journal-title":"Lancet"},{"issue":"3","key":"9601_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5214\/ans.0972.7531.210308","volume":"21","author":"AA Rikani","year":"2014","unstructured":"Rikani AA, Choudhry Z, Choudhry AM, Rizvi N, Ikram H, Mobassarah NJ, Tulli S (2014) The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann Neurosci 21(3):112\u2013114. doi: 10.5214\/ans.0972.7531.210308","journal-title":"Ann Neurosci"},{"issue":"1","key":"9601_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83\u201398. doi: 10.1016\/S1474-4422(10)70245-3","journal-title":"Lancet Neurol"},{"issue":"9","key":"9601_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord 27(9):1083\u20131091. doi: 10.1002\/mds.25075","journal-title":"Mov Disord"},{"issue":"2","key":"9601_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1602\/neurorx.1.2.255","volume":"1","author":"RH Myers","year":"2004","unstructured":"Myers RH (2004) Huntington's disease genetics. NeuroRx 1(2):255\u2013262. doi: 10.1602\/neurorx.1.2.255","journal-title":"NeuroRx"},{"key":"9601_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26331","author":"KM Shannon","year":"2015","unstructured":"Shannon KM, Fraint A (2015) Therapeutic advances in Huntington's disease. Mov Disord. doi: 10.1002\/mds.26331","journal-title":"Mov Disord"},{"issue":"4","key":"9601_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663\u2013676. doi: 10.1016\/j.cell.2006.07.024","journal-title":"Cell"},{"issue":"5","key":"9601_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861\u2013872. doi: 10.1016\/j.cell.2007.11.019","journal-title":"Cell"},{"issue":"1","key":"9601_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nbt1374","volume":"26","author":"M Nakagawa","year":"2008","unstructured":"Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y et al (2008) Generation of induced pluripotent stem cells without myc from mouse and human fibroblasts. Nat Biotechnol 26(1):101\u2013106. doi: 10.1038\/nbt1374","journal-title":"Nat Biotechnol"},{"issue":"1","key":"9601_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2009.03.034","volume":"137","author":"S Yamanaka","year":"2009","unstructured":"Yamanaka S (2009) A fresh look at iPS cells. Cell 137(1):13\u201317. doi: 10.1016\/j.cell.2009.03.034","journal-title":"Cell"},{"issue":"6","key":"9601_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/ncb1589","volume":"9","author":"S Masui","year":"2007","unstructured":"Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A et al (2007) Pluripotency governed by Sox2 via regulation of Oct3\/4 expression in mouse embryonic stem cells. Nat Cell Biol 9(6):625\u2013635. doi: 10.1038\/ncb1589","journal-title":"Nat Cell Biol"},{"issue":"5","key":"9601_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0896-6273(03)00497-5","volume":"39","author":"V Graham","year":"2003","unstructured":"Graham V, Khudyakov J, Ellis P, Pevny L (2003) SOX2 functions to maintain neural progenitor identity. Neuron 39(5):749\u2013765. doi: 10.1016\/S0896-6273(03)00497-5","journal-title":"Neuron"},{"key":"9601_CR13","doi-asserted-by":"publisher","unstructured":"Dametti S, Faravelli I, Ruggieri M, Ramirez A, Nizzardo M, Corti S (2015) Experimental advances towards neural regeneration from induced stem cells to direct in vivo reprogramming. Mol Neurobiol:1\u20138. doi: 10.1007\/s12035-015-9181-7","DOI":"10.1007\/s12035-015-9181-7"},{"issue":"R1","key":"9601_CR14","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1093\/hmg\/ddu204","volume":"23","author":"CA Ross","year":"2014","unstructured":"Ross CA, Akimov SS (2014) Human-induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet 23(R1):R17\u2013R26. doi: 10.1093\/hmg\/ddu204","journal-title":"Hum Mol Genet"},{"issue":"1","key":"9601_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5607\/en.2014.23.1.45","volume":"23","author":"SS Choi","year":"2014","unstructured":"Choi SS, Lee SR, Kim SU, Lee HJ (2014) Alzheimer's disease and stem cell therapy. Exp Neurobiol 23(1):45\u201352. doi: 10.5607\/en.2014.23.1.45","journal-title":"Exp Neurobiol"},{"issue":"1","key":"9601_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12035-014-8867-6","volume":"52","author":"L Cao","year":"2015","unstructured":"Cao L, Tan L, Jiang T, Zhu XC, Yu JT (2015) Induced pluripotent stem cells for disease modeling and drug discovery in neurodegenerative diseases. Mol Neurobiol 52(1):244\u2013255. doi: 10.1007\/s12035-014-8867-6","journal-title":"Mol Neurobiol"},{"issue":"1","key":"9601_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s12035-014-8883-6","volume":"52","author":"G Upadhyay","year":"2015","unstructured":"Upadhyay G, Shankar S, Srivastava RK (2015) Stem cells in neurological disorders: emerging therapy with stunning hopes. Mol Neurobiol 52(1):610\u2013625. doi: 10.1007\/s12035-014-8883-6","journal-title":"Mol Neurobiol"},{"issue":"12","key":"9601_CR18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/nrn1806","volume":"6","author":"E Cattaneo","year":"2005","unstructured":"Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 6(12):919\u2013930. doi: 10.1038\/nrn1806","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"9601_CR19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","volume":"81","author":"J Nasir","year":"1995","unstructured":"Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD et al (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81(5):811\u2013823","journal-title":"Cell"},{"key":"9601_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-3-642-45106-5_14","volume":"220","author":"C Zuccato","year":"2014","unstructured":"Zuccato C, Cattaneo E (2014) Huntington's disease. Handb Exp Pharmacol 220:357\u2013409. doi: 10.1007\/978-3-642-45106-5_14","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"9601_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90(3):905\u2013981. doi: 10.1152\/physrev.00041.2009","journal-title":"Physiol Rev"},{"issue":"1","key":"9601_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00401-007-0306-6","volume":"115","author":"JP Vonsattel","year":"2008","unstructured":"Vonsattel JP (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol 115(1):55\u201369. doi: 10.1007\/s00401-007-0306-6","journal-title":"Acta Neuropathol"},{"issue":"1","key":"9601_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","volume":"238","author":"M Arrasate","year":"2012","unstructured":"Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington's disease. Exp Neurol 238(1):1\u201311. doi: 10.1016\/j.expneurol.2011.12.013","journal-title":"Exp Neurol"},{"issue":"7","key":"9601_CR24","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","volume":"19","author":"CA Gutekunst","year":"1999","unstructured":"Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ et al (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19(7):2522\u20132534","journal-title":"J Neurosci"},{"issue":"1","key":"9601_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ana.24174","volume":"76","author":"F Cicchetti","year":"2014","unstructured":"Cicchetti F, Lacroix S, Cisbani G, Vallieres N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper JN et al (2014) Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 76(1):31\u201342. doi: 10.1002\/ana.24174","journal-title":"Ann Neurol"},{"key":"9601_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-015-9188-0","author":"N Brustovetsky","year":"2015","unstructured":"Brustovetsky N (2015) Mutant huntingtin and elusive defects in oxidative metabolism and mitochondrial calcium handling. Mol Neurobiol. doi: 10.1007\/s12035-015-9188-0","journal-title":"Mol Neurobiol"},{"issue":"3","key":"9601_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.arcmed.2007.11.011","volume":"39","author":"AM Estrada Sanchez","year":"2008","unstructured":"Estrada Sanchez AM, Mejia-Toiber J, Massieu L (2008) Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 39(3):265\u2013276. doi: 10.1016\/j.arcmed.2007.11.011","journal-title":"Arch Med Res"},{"issue":"7","key":"9601_CR28","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.drudis.2014.02.006","volume":"19","author":"MD Sepers","year":"2014","unstructured":"Sepers MD, Raymond LA (2014) Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. Drug Discov Today 19(7):990\u2013996. doi: 10.1016\/j.drudis.2014.02.006","journal-title":"Drug Discov Today"},{"issue":"4","key":"9601_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.pneurobio.2007.03.004","volume":"83","author":"JH Cha","year":"2007","unstructured":"Cha JH (2007) Transcriptional signatures in Huntington's disease. Prog Neurobiol 83(4):228\u2013248. doi: 10.1016\/j.pneurobio.2007.03.004","journal-title":"Prog Neurobiol"},{"issue":"1","key":"9601_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12035-014-8715-8","volume":"51","author":"L Valor","year":"2015","unstructured":"Valor L (2015) Transcription, epigenetics and ameliorative strategies in Huntington\u2019s disease: a genome-wide perspective. Mol Neurobiol 51(1):406\u2013423. doi: 10.1007\/s12035-014-8715-8","journal-title":"Mol Neurobiol"},{"issue":"5","key":"9601_CR31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/MCB.22.5.1277-1287.2002","volume":"22","author":"SH Li","year":"2002","unstructured":"Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li XJ (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22(5):1277\u20131287","journal-title":"Mol Cell Biol"},{"issue":"12","key":"9601_CR32","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1073\/pnas.100110097","volume":"97","author":"JS Steffan","year":"2000","unstructured":"Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP et al (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97(12):6763\u20136768. doi: 10.1073\/pnas.100110097","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5512","key":"9601_CR33","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1126\/science.1056784","volume":"291","author":"FC Nucifora Jr","year":"2001","unstructured":"Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, Takahashi H, Tsuji S et al (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291(5512):2423\u20132428. doi: 10.1126\/science.1056784","journal-title":"Science"},{"issue":"7154","key":"9601_CR34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nature06022","volume":"448","author":"EJ Bennett","year":"2007","unstructured":"Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H et al (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448(7154):704\u2013708. doi: 10.1038\/nature06022","journal-title":"Nature"},{"key":"9601_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fnmol.2014.00077","volume":"7","author":"Z Ortega","year":"2014","unstructured":"Ortega Z, Lucas JJ (2014) Ubiquitin-proteasome system involvement in Huntington's disease. Front Mol Neurosci 7:77. doi: 10.3389\/fnmol.2014.00077","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"9601_CR36","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1016\/j.ddtec.2012.09.010","volume":"10","author":"S Sarkar","year":"2013","unstructured":"Sarkar S (2013) Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington's disease and other neurodegenerative disorders. Drug Discov Today Technol 10(1):e137\u2013e144. doi: 10.1016\/j.ddtec.2012.09.010","journal-title":"Drug Discov Today Technol"},{"key":"9601_CR37","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fncel.2014.00218","volume":"8","author":"J Margulis","year":"2014","unstructured":"Margulis J, Finkbeiner S (2014) Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease. Front Cell Neurosci 8:218. doi: 10.3389\/fncel.2014.00218","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"9601_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.drudis.2014.02.014","volume":"19","author":"CJ Cortes","year":"2014","unstructured":"Cortes CJ, La Spada AR (2014) The many faces of autophagy dysfunction in Huntington's disease: from mechanism to therapy. Drug Discov Today 19(7):963\u2013971. doi: 10.1016\/j.drudis.2014.02.014","journal-title":"Drug Discov Today"},{"issue":"9942","key":"9601_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s0140-6736(14)61010-2","volume":"384","author":"AH Schapira","year":"2014","unstructured":"Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384(9942):545\u2013555. doi: 10.1016\/s0140-6736(14)61010-2","journal-title":"Lancet"},{"issue":"11","key":"9601_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/mds.26014","volume":"29","author":"A Killoran","year":"2014","unstructured":"Killoran A, Biglan KM (2014) Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? Mov Disord 29(11):1404\u20131413. doi: 10.1002\/mds.26014","journal-title":"Mov Disord"},{"issue":"1","key":"9601_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"S Frank","year":"2014","unstructured":"Frank S (2014) Treatment of Huntington's disease. Neurotherapeutics 11(1):153\u2013160. doi: 10.1007\/s13311-013-0244-z","journal-title":"Neurotherapeutics"},{"issue":"11","key":"9601_CR42","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1002\/mds.26021","volume":"29","author":"C Sampaio","year":"2014","unstructured":"Sampaio C, Borowsky B, Reilmann R (2014) Clinical trials in Huntington's disease: interventions in early clinical development and newer methodological approaches. Mov Disord 29(11):1419\u20131428. doi: 10.1002\/mds.26021","journal-title":"Mov Disord"},{"issue":"11","key":"9601_CR43","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/mds.26020","volume":"29","author":"N Aronin","year":"2014","unstructured":"Aronin N, DiFiglia M (2014) Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 29(11):1455\u20131461. doi: 10.1002\/mds.26020","journal-title":"Mov Disord"},{"issue":"1","key":"9601_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","volume":"20","author":"BM Godinho","year":"2015","unstructured":"Godinho BM, Malhotra M, O'Driscoll CM, Cryan JF (2015) Delivering a disease-modifying treatment for Huntington's disease. Drug Discov Today 20(1):50\u201364. doi: 10.1016\/j.drudis.2014.09.011","journal-title":"Drug Discov Today"},{"key":"9601_CR45","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2015.0547","author":"ME Ostergaard","year":"2015","unstructured":"Ostergaard ME, Kumar P, Nichols J, Watt A, Sharma PK, Nielsen P, Seth PP (2015) Allele-selective inhibition of mutant huntingtin with 2-Thio- and C5- triazolylphenyl-deoxythymidine-modified antisense oligonucleotides. Nucleic Acid Ther. doi: 10.1089\/nat.2015.0547","journal-title":"Nucleic Acid Ther"},{"issue":"12","key":"9601_CR46","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF et al (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin. Mol Ther 19(12):2178\u20132185. doi: 10.1038\/mt.2011.201","journal-title":"Mol Ther"},{"issue":"10","key":"9601_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 14(10):708\u2013721. doi: 10.1038\/nrn3570","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"9601_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12035-012-8315-4","volume":"46","author":"M Figiel","year":"2012","unstructured":"Figiel M, Szlachcic W, Switonski P, Gabka A, Krzyzosiak W (2012) Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol 46(2):393\u2013429. doi: 10.1007\/s12035-012-8315-4","journal-title":"Mol Neurobiol"},{"issue":"6","key":"9601_CR49","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.stem.2013.05.016","volume":"12","author":"T Merkle Florian","year":"2013","unstructured":"Merkle Florian T, Eggan K (2013) Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 12(6):656\u2013668. doi: 10.1016\/j.stem.2013.05.016","journal-title":"Cell Stem Cell"},{"issue":"11","key":"9601_CR50","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/mds.26006","volume":"29","author":"L Menalled","year":"2014","unstructured":"Menalled L, Brunner D (2014) Animal models of Huntington's disease for translation to the clinic: best practices. Mov Disord 29(11):1375\u20131390. doi: 10.1002\/mds.26006","journal-title":"Mov Disord"},{"issue":"12","key":"9601_CR51","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.5966\/sctm.2014-0102","volume":"3","author":"X Zeng","year":"2014","unstructured":"Zeng X, Hunsberger JG, Simeonov A, Malik N, Pei Y, Rao M (2014) Concise review: modeling central nervous system diseases using induced pluripotent stem cells. Stem Cells Transl Med 3(12):1418\u20131428. doi: 10.5966\/sctm.2014-0102","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"9601_CR52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s13311-011-0079-4","volume":"8","author":"C Nicoleau","year":"2011","unstructured":"Nicoleau C, Viegas P, Peschanski M, Perrier AL (2011) Human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges human pluripotent stem cell therapy for Huntington's disease: technical, immunological, and safety challenges. Neurotherapeutics 8(4):562\u2013576. doi: 10.1007\/s13311-011-0079-4","journal-title":"Neurotherapeutics"},{"key":"9601_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mcn.2013.02.005","volume":"56","author":"JA Kaye","year":"2013","unstructured":"Kaye JA, Finkbeiner S (2013) Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 56:50\u201364. doi: 10.1016\/j.mcn.2013.02.005","journal-title":"Mol Cell Neurosci"},{"issue":"6","key":"9601_CR54","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nn.4014","volume":"18","author":"K Becanovic","year":"2015","unstructured":"Becanovic K, Norremolle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G et al (2015) A SNP in the HTT promoter alters NF-kappaB binding and is a bidirectional genetic modifier of Huntington disease. Nat Nuerosci 18(6):807\u2013816. doi: 10.1038\/nn.4014","journal-title":"Nat Nuerosci"},{"issue":"2","key":"9601_CR55","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","volume":"11","author":"MC An","year":"2012","unstructured":"An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM (2012) Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11(2):253\u2013263. doi: 10.1016\/j.stem.2012.04.026","journal-title":"Cell Stem Cell"},{"issue":"1","key":"9601_CR56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/brainsci4010202","volume":"4","author":"AT Crane","year":"2014","unstructured":"Crane AT, Rossignol J, Dunbar GL (2014) Use of genetically altered stem cells for the treatment of Huntington's disease. Brain Sci 4(1):202\u2013219. doi: 10.3390\/brainsci4010202","journal-title":"Brain Sci"},{"issue":"5","key":"9601_CR57","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","volume":"134","author":"IH Park","year":"2008","unstructured":"Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C et al (2008) Disease-specific induced pluripotent stem cells. Cell 134(5):877\u2013886. doi: 10.1016\/j.cell.2008.07.041","journal-title":"Cell"},{"key":"9601_CR58","doi-asserted-by":"publisher","first-page":"Rrn1193","DOI":"10.1371\/currents.RRN1193","volume":"2","author":"N Zhang","year":"2010","unstructured":"Zhang N, An MC, Montoro D, Ellerby LM (2010) Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Currents 2:Rrn1193. doi: 10.1371\/currents.RRN1193","journal-title":"PLoS Currents"},{"issue":"3","key":"9601_CR59","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1042\/bj20111495","volume":"446","author":"JI Chae","year":"2012","unstructured":"Chae JI, Kim DW, Lee N, Jeon YJ, Jeon I, Kwon J, Kim J, Soh Y et al (2012) Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J 446(3):359\u2013371. doi: 10.1042\/bj20111495","journal-title":"Biochem J"},{"key":"9601_CR60","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.019406","author":"WJ Szlachcic","year":"2015","unstructured":"Szlachcic WJ, Switonski PM, Krzyzosiak WJ, Figlerowicz M, Figiel M (2015) Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway. Dis Model Mech. doi: 10.1242\/dmm.019406","journal-title":"Dis Model Mech"},{"issue":"1","key":"9601_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2011.12.042","volume":"46","author":"S Camnasio","year":"2012","unstructured":"Camnasio S, Delli Carri A, Lombardo A, Grad I, Mariotti C, Castucci A, Rozell B, Lo Riso P et al (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 46(1):41\u201351. doi: 10.1016\/j.nbd.2011.12.042","journal-title":"Neurobiol Dis"},{"issue":"2","key":"9601_CR62","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.stem.2012.04.027","volume":"11","author":"Consortium THi","year":"2012","unstructured":"Consortium THi (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11(2):264\u2013278. doi: 10.1016\/j.stem.2012.04.027","journal-title":"Cell Stem Cell"},{"key":"9601_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv080","author":"VB Mattis","year":"2015","unstructured":"Mattis VB, Tom C, Akimov S, Saeedian J, Ostergaard ME, Southwell AL, Doty CN, Ornelas L et al (2015) HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet. doi: 10.1093\/hmg\/ddv080","journal-title":"Hum Mol Genet"},{"key":"9601_CR64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1756-6606-5-17","volume":"5","author":"TA Juopperi","year":"2012","unstructured":"Juopperi TA, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, Ming GL, Song H (2012) Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol Brain 5:17. doi: 10.1186\/1756-6606-5-17","journal-title":"Mol Brain"},{"issue":"8","key":"9601_CR65","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/01.wnr.0000127073.66692.8f","volume":"15","author":"E Nagata","year":"2004","unstructured":"Nagata E, Sawa A, Ross CA, Snyder SH (2004) Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. Neuroreport 15(8):1325\u20131328","journal-title":"Neuroreport"},{"issue":"9","key":"9601_CR66","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/stem.1135","volume":"30","author":"I Jeon","year":"2012","unstructured":"Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C et al (2012) Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 30(9):2054\u20132062. doi: 10.1002\/stem.1135","journal-title":"Stem Cells"},{"key":"9601_CR67","doi-asserted-by":"publisher","unstructured":"An MC, O'Brien RN, Zhang N, Patra BN, De La Cruz M, Ray A, Ellerby LM (2014) Polyglutamine disease modeling: epitope based screen for homologous recombination using CRISPR\/Cas9 System. PLoS Curr 6. doi: 10.1371\/currents.hd.0242d2e7ad72225efa72f6964589369a","DOI":"10.1371\/currents.hd.0242d2e7ad72225efa72f6964589369a"},{"issue":"6","key":"9601_CR68","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.stem.2013.05.018","volume":"12","author":"DX Yu","year":"2013","unstructured":"Yu DX, Marchetto MC, Gage FH (2013) Therapeutic translation of iPSCs for treating neurological disease. Cell Stem Cell 12(6):678\u2013688. doi: 10.1016\/j.stem.2013.05.018","journal-title":"Cell Stem Cell"},{"issue":"5","key":"9601_CR69","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/1087057112474468","volume":"18","author":"J Peng","year":"2013","unstructured":"Peng J, Liu Q, Rao MS, Zeng X (2013) Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models. J Biomol Screen 18(5):522\u2013533. doi: 10.1177\/1087057112474468","journal-title":"J Biomol Screen"},{"issue":"9\u201310","key":"9601_CR70","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.drudis.2009.02.006","volume":"14","author":"W Fecke","year":"2009","unstructured":"Fecke W, Gianfriddo M, Gaviraghi G, Terstappen GC, Heitz F (2009) Small molecule drug discovery for Huntington's disease. Drug Discov Today 14(9\u201310):453\u2013464. doi: 10.1016\/j.drudis.2009.02.006","journal-title":"Drug Discov Today"},{"issue":"2","key":"9601_CR71","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.stem.2012.07.015","volume":"11","author":"A Perrier","year":"2012","unstructured":"Perrier A, Peschanski M (2012) How can human pluripotent stem cells help decipher and cure Huntington\u2019s disease? Cell Stem Cell 11(2):153\u2013161. doi: 10.1016\/j.stem.2012.07.015","journal-title":"Cell Stem Cell"},{"issue":"8","key":"9601_CR72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/092986710790514480","volume":"17","author":"I Gunaseeli","year":"2010","unstructured":"Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A (2010) Induced pluripotent stem cells as a model for accelerated patient- and disease-specific drug discovery. Curr Med Chem 17(8):759\u2013766","journal-title":"Curr Med Chem"},{"issue":"6","key":"9601_CR73","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.stem.2013.05.011","volume":"12","author":"SJ Engle","year":"2013","unstructured":"Engle SJ, Puppala D (2013) Integrating human pluripotent stem cells into drug development. Cell Stem Cell 12(6):669\u2013677. doi: 10.1016\/j.stem.2013.05.011","journal-title":"Cell Stem Cell"},{"issue":"11","key":"9601_CR74","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/mds.26026","volume":"29","author":"A Rosser","year":"2014","unstructured":"Rosser A, Svendsen CN (2014) Stem cells for cell replacement therapy: a therapeutic strategy for HD? Mov Disord 29(11):1446\u20131454. doi: 10.1002\/mds.26026","journal-title":"Mov Disord"},{"issue":"7","key":"9601_CR75","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.drudis.2014.02.012","volume":"19","author":"Y Chen","year":"2014","unstructured":"Chen Y, Carter RL, Cho IK, Chan AW (2014) Cell-based therapies for Huntington's disease. Drug Discov Today 19(7):980\u2013984. doi: 10.1016\/j.drudis.2014.02.012","journal-title":"Drug Discov Today"},{"issue":"1","key":"9601_CR76","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1006\/exnr.1999.7239","volume":"161","author":"A Bachoud-Levi","year":"2000","unstructured":"Bachoud-Levi A, Bourdet C, Brugieres P, Nguyen JP, Grandmougin T, Haddad B, Jeny R, Bartolomeo P et al (2000) Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp Neurol 161(1):194\u2013202. doi: 10.1006\/exnr.1999.7239","journal-title":"Exp Neurol"},{"issue":"9246","key":"9601_CR77","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","volume":"356","author":"AC Bachoud-Levi","year":"2000","unstructured":"Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V et al (2000) Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356(9246):1975\u20131979","journal-title":"Lancet"},{"issue":"3","key":"9601_CR78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0963-6897(97)00028-6","volume":"6","author":"LM Philpott","year":"1997","unstructured":"Philpott LM, Kopyov OV, Lee AJ, Jacques S, Duma CM, Caine S, Yang M, Eagle KS (1997) Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 6(3):203\u2013212","journal-title":"Cell Transplant"},{"key":"9601_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-62703-411-1_2","volume":"1010","author":"CA Antoniades","year":"2013","unstructured":"Antoniades CA, Watts C (2013) Huntington's disease and cell therapies: past, present, and future. Methods Mol Biol 1010:19\u201332. doi: 10.1007\/978-1-62703-411-1_2","journal-title":"Methods Mol Biol"},{"issue":"43","key":"9601_CR80","doi-asserted-by":"publisher","first-page":"16707","DOI":"10.1073\/pnas.0808488105","volume":"105","author":"L Aubry","year":"2008","unstructured":"Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL (2008) Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 105(43):16707\u201316712. doi: 10.1073\/pnas.0808488105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"9601_CR81","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.stem.2012.01.021","volume":"10","author":"L Ma","year":"2012","unstructured":"Ma L, Hu B, Liu Y, Vermilyea SC, Liu H, Gao L, Sun Y, Zhang X et al (2012) Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 10(4):455\u2013464. doi: 10.1016\/j.stem.2012.01.021","journal-title":"Cell Stem Cell"},{"issue":"2","key":"9601_CR82","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1242\/dev.084608","volume":"140","author":"A Delli Carri","year":"2013","unstructured":"Delli Carri A, Onorati M, Lelos MJ, Castiglioni V, Faedo A, Menon R, Camnasio S, Vuono R et al (2013) Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 140(2):301\u2013312. doi: 10.1242\/dev.084608","journal-title":"Development"},{"issue":"5","key":"9601_CR83","doi-asserted-by":"publisher","first-page":"620","DOI":"10.5966\/sctm.2013-0151","volume":"3","author":"KD Fink","year":"2014","unstructured":"Fink KD, Crane AT, Leveque X, Dues DJ, Huffman LD, Moore AC, Story DT, Dejonge RE et al (2014) Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease. Stem Cells Transl Med 3(5):620\u2013631. doi: 10.5966\/sctm.2013-0151","journal-title":"Stem Cells Transl Med"},{"issue":"7","key":"9601_CR84","doi-asserted-by":"publisher","first-page":"e101185","DOI":"10.1371\/journal.pone.0101185","volume":"9","author":"S Mu","year":"2014","unstructured":"Mu S, Wang J, Zhou G, Peng W, He Z, Zhao Z, Mo C, Qu J et al (2014) Transplantation of induced pluripotent stem cells improves functional recovery in Huntington's disease rat model. PLoS One 9(7):e101185. doi: 10.1371\/journal.pone.0101185","journal-title":"PLoS One"},{"issue":"1","key":"9601_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.14001","volume":"7","author":"W Im","year":"2014","unstructured":"Im W, Kim M (2014) Cell therapy strategies vs. paracrine effect in Huntington's disease. J Mov Disord 7(1):1\u20136. doi: 10.14802\/jmd.14001","journal-title":"J Mov Disord"},{"issue":"1","key":"9601_CR86","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12035-011-8219-8","volume":"45","author":"SD Olson","year":"2012","unstructured":"Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J, Stewart H, McGee J et al (2012) Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 45(1):87\u201398. doi: 10.1007\/s12035-011-8219-8","journal-title":"Mol Neurobiol"},{"key":"9601_CR87","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fncel.2014.00316","volume":"8","author":"G Liu","year":"2014","unstructured":"Liu G, Rustom N, Litteljohn D, Bobyn J, Rudyk C, Anisman H, Hayley S (2014) Use of induced pluripotent stem cell derived neurons engineered to express BDNF for modulation of stressor related pathology. Front Cell Neurosci 8:316. doi: 10.3389\/fncel.2014.00316","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"9601_CR88","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s1474-4422(06)70381-7","volume":"5","author":"AC Bachoud-Levi","year":"2006","unstructured":"Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, Boisse MF, Maison P, Baudic S, Ribeiro MJ et al (2006) Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 5(4):303\u2013309. doi: 10.1016\/s1474-4422(06)70381-7","journal-title":"Lancet Neurol"},{"issue":"6","key":"9601_CR89","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","volume":"84","author":"RA Barker","year":"2013","unstructured":"Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S et al (2013) The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 84(6):657\u2013665. doi: 10.1136\/jnnp-2012-302441","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"30","key":"9601_CR90","doi-asserted-by":"publisher","first-page":"12483","DOI":"10.1073\/pnas.0904239106","volume":"106","author":"F Cicchetti","year":"2009","unstructured":"Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, Li XJ, Parker JR et al (2009) Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 106(30):12483\u201312488. doi: 10.1073\/pnas.0904239106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"9601_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15283\/ijsc.2014.7.1.43","volume":"7","author":"I Jeon","year":"2014","unstructured":"Jeon I, Choi C, Lee N, Im W, Kim M, Oh SH, Park IH, Kim HS et al (2014) In vivo roles of a patient-derived induced pluripotent stem cell Line (HD72-iPSC) in the YAC128 model of Huntington's disease. Int J Stem Cells 7(1):43\u201347. doi: 10.15283\/ijsc.2014.7.1.43","journal-title":"Int J Stem Cells"},{"issue":"23","key":"9601_CR92","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/hmg\/11.23.2905","volume":"11","author":"W Yang","year":"2002","unstructured":"Yang W, Dunlap JR, Andrews RB, Wetzel R (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11(23):2905\u20132917","journal-title":"Hum Mol Genet"},{"issue":"2","key":"9601_CR93","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ncb1830","volume":"11","author":"PH Ren","year":"2009","unstructured":"Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 11(2):219\u2013225. doi: 10.1038\/ncb1830","journal-title":"Nat Cell Biol"},{"key":"9601_CR94","doi-asserted-by":"publisher","first-page":"Rrn1210","DOI":"10.1371\/currents.RRN1210","volume":"3","author":"F Herrera","year":"2011","unstructured":"Herrera F, Tenreiro S, Miller-Fleming L, Outeiro TF (2011) Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr 3:Rrn1210. doi: 10.1371\/currents.RRN1210","journal-title":"PLoS Curr"},{"issue":"Pt 16","key":"9601_CR95","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1242\/jcs.126086","volume":"126","author":"M Costanzo","year":"2013","unstructured":"Costanzo M, Abounit S, Marzo L, Danckaert A, Chamoun Z, Roux P, Zurzolo C (2013) Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J Cell Sci 126(Pt 16):3678\u20133685. doi: 10.1242\/jcs.126086","journal-title":"J Cell Sci"},{"issue":"8","key":"9601_CR96","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/nn.3761","volume":"17","author":"E Pecho-Vrieseling","year":"2014","unstructured":"Pecho-Vrieseling E, Rieker C, Fuchs S, Bleckmann D, Esposito MS, Botta P, Goldstein C, Bernhard M et al (2014) Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat Neurosci 17(8):1064\u20131072. doi: 10.1038\/nn.3761","journal-title":"Nat Neurosci"},{"key":"9601_CR97","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.1038\/ncomms7768","volume":"6","author":"MM Pearce","year":"2015","unstructured":"Pearce MM, Spartz EJ, Hong W, Luo L, Kopito RR (2015) Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the drosophila brain. Nat Commun 6:6768. doi: 10.1038\/ncomms7768","journal-title":"Nat Commun"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-015-9601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-015-9601-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-015-9601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-015-9601-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T05:52:56Z","timestamp":1589608376000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-015-9601-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":97,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["9601"],"URL":"https:\/\/doi.org\/10.1007\/s12035-015-9601-8","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]}}}